Par to ship generic Tambocor
Executive Summary
Par's generic version of 3M's antiarrhythmic Tambocor expected to ship within 30 days, company says May 3. Par expects to have about 150 days of generic exclusivity. The company believes generic exclusivity was triggered by an appellate court decision invalidating 3M's Tambocor patents. 3M had appealed a May 2001 Minneapolis federal court verdict in favor of Barr, which was second to file an ANDA for flecainide (1"The Pink Sheet" April 8, p. 26)...
You may also be interested in...
Generic Success In Patent Cases May Slow Momentum For Waxman/Hatch Fix
A string of recent patent victories for the generic industry may take some momentum away from the drive for Waxman/Hatch reform
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.